Posted by Michael Wonder on 01 Sep 2024
FDA authorises updated Novavax COVID-19 vaccine to better protect against currently circulating variants
30 August 2024 - Today, the US FDA granted emergency use authorisation for an updated version of the Novavax COVID-19 vaccine that more closely targets currently circulating variants to provide better protection against serious consequences of COVID-19, including hospitalisation and death.
The updated vaccine is authorised for use in individuals 12 years of age and older. It includes a monovalent component that corresponds to the Omicron variant JN.1 strain of SARS-CoV-2.
